Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.

Authors:
Grażyna Majkowska-Skrobek Daria Augustyniak Paweł Lis Anna Bartkowiak Mykhailo Gonchar Young H Ko Peter L Pedersen Andre Goffeau Stanisław Ułaszewski

Anticancer Drugs 2014 Jul;25(6):673-82

aInstitute of Genetics and Microbiology, University of Wrocław, Wrocław, Poland bInstitute of Cell Biology, NAS of Ukraine, Lviv, Ukraine cKoDiscovery LLC, UM BioPark, Innovation Center dDepartments of Biological Chemistry and Oncology, Member Sidney Kimmel Comprehensive Cancer Center, Member Center for Obesity Research and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA eInstitute of Life Sciences, Catholic University of Louvain, Place de l'Université, Louvain-la-Neuve, Belgium.

The small molecule 3-bromopyruvate (3-BP), which has emerged recently as the first member of a new class of potent anticancer agents, was tested for its capacity to kill multiple myeloma (MM) cancer cells. Human MM cells (RPMI 8226) begin to lose viability significantly within 8 h of incubation in the presence of 3-BP. The Km (0.3 mmol/l) for intracellular accumulation of 3-BP in MM cells is 24 times lower than that in control cells (7.2 mmol/l). Therefore, the uptake of 3-BP by MM cells is significantly higher than that by peripheral blood mononuclear cells. Further, the IC50 values for human MM cells and control peripheral blood mononuclear cells are 24 and 58 µmol/l, respectively. Therefore, specificity and selectivity of 3-BP toward MM cancer cells are evident on the basis of the above. In MM cells the transcription levels of the gene encoding the monocarboxylate transporter MCT1 is significantly amplified compared with control cells. The level of intracellular ATP in MM cells decreases by over 90% within 1 h after addition of 100 µmol/l 3-BP. The cytotoxicity of 3-BP, exemplified by a marked decrease in viability of MM cells, is potentiated by the inhibitor of glutathione synthesis buthionine sulfoximine. In addition, the lack of mutagenicity and its superior capacity relative to Glivec to kill MM cancer cells are presented in this study.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000094DOI Listing
July 2014

Publication Analysis

Top Keywords

cells
15
cancer cells
12
small molecule
8
human cells
8
3-bp cells
8
molecule 3-bromopyruvate
8
mononuclear cells
8
control cells
8
blood mononuclear
8
multiple myeloma
8
peripheral blood
8
3-bp
7
evident basis
4
amplified compared
4
mct1 amplified
4
uptake 3-bp
4
transporter mct1
4
monocarboxylate transporter
4
encoding monocarboxylate
4
gene encoding
4

Keyword Occurance

Similar Publications

Type III-A CRISPR-Cas systems as a versatile gene knockdown technology.

Authors:
Walter T Woodside Nikita Vantsev Ryan J Catchpole Sandra C Garrett Sara Olson Brenton R Graveley Michael P Terns

RNA 2022 May 26. Epub 2022 May 26.

University of Georgia;

CRISPR-Cas systems are functionally diverse prokaryotic anti-viral defense systems, which encompass six distinct types (I-VI) that each encode different effector Cas nucleases with distinct nucleic acid cleavage specificities. By harnessing the unique attributes of the various CRISPR-Cas systems, a range of innovative CRISPR-based DNA and RNA targeting tools and technologies have been developed. Here, we exploit the ability of type III-A CRISPR-Cas systems to carry out RNA-guided and sequence-specific target RNA cleavage for establishment of research tools for post-transcriptional control of gene expression. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Transplantation in the Age of Precision Medicine: The Emerging Field of Treg Therapy.

Authors:
Charles G Rickert James F Markmann

Semin Nephrol 2022 Jan;42(1):76-85

Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Division of Transplantation, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:

Solid organ transplantation has experienced incredible success over the past half century in rescuing patients with end-stage organ failure and bestowing them with a high quality of life. This success in large part is the result of advances in immunosuppression, however, these regimens come with significant costs including opportunistic infections, and in some cases, direct toxicity to the newly transplanted organs. Further advances are needed. Read More

View Article and Full-Text PDF
January 2022
Similar Publications

Immune determinants of endometrial receptivity: a biological perspective.

Authors:
Sarah A Robertson Lachlan M Moldenhauer Ella S Green Alison S Care M Louise Hull

Fertil Steril 2022 Jun;117(6):1107-1120

Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.

Immune cells are essential for endometrial receptivity to embryo implantation and early placental development. They exert tissue-remodeling and immune regulatory roles-acting to promote epithelial attachment competence, regulate the differentiation of decidual cells, remodel the uterine vasculature, control and resolve inflammatory activation, and suppress destructive immunity to paternally inherited alloantigens. From a biological perspective, the endometrial immune response exerts a form of "quality control"-it promotes implantation success when conditions are favorable but constrains receptivity when physiological circumstances are not ideal. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

A combined application of molecular docking technology and indirect ELISA for the serodiagnosis of bovine tuberculosis.

Authors:
Shengnan Song Qian Zhang Hang Yang Jia Guo Mingguo Xu Ningning Yang Jihai Yi Zhen Wang Chuangfu Chen

J Vet Sci 2022 May;23(3):e50

College of Animal Science and Technology, Shihezi University, Shihezi 832000, China.

Background: There is an urgent need to find reliable and rapid bovine tuberculosis (bTB) diagnostics in response to the rising prevalence of bTB worldwide. Toll-like receptor 2 (TLR2) recognizes components of bTB and initiates antigen-presenting cells to mediate humoral immunity. Evaluating the affinity of antigens with TLR2 can form the basis of a new method for the diagnosis of bTB based on humoral immunity. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Unique role for lncRNA HOTAIR in defining depot-specific gene expression patterns in human adipose-derived stem cells.

Authors:
Edina Erdos Adeline Divoux Katalin Sandor Laszlo Halasz Steven R Smith Timothy F Osborne

Genes Dev 2022 May 26. Epub 2022 May 26.

Division of Diabetes Endocrinology and Metabolism, Johns Hopkins University School of Medicine; Institute for Fundamental Biomedical Research, Johns Hopkins All Children's Hospital, St. Petersburg, Florida 33701, USA.

Accumulation of fat above the waist is an important risk factor in developing obesity-related comorbidities independently of BMI or total fat mass. Deciphering the gene regulatory programs of the adipose tissue precursor cells within upper body or abdominal (ABD) and lower body or gluteofemoral (GF) depots is important to understand their differential capacity for lipid accumulation, maturation, and disease risk. Previous studies identified the HOX transcript antisense intergenic RNA (HOTAIR) as a GF-specific lncRNA; however, its role in adipose tissue biology is still unclear. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap